SAP Partners with Gurobi to Enhance and Expand Optimization Capabilities Across its Enterprise Application Software Suite
13.5.2020 13:00:00 EEST | Business Wire | Press release
Gurobi Optimization, LLC today announced that it has been selected by SAP SE (NYSE: SAP) as the premier, enterprise-wide supplier for mathematical optimization technology, and has entered into a long-term strategic partnership with SAP to enhance and expand the use of mathematical optimization across SAP’s enterprise application software suite. As a result of the partnership, SAP and Gurobi will be able to more effectively collaborate on innovations that will improve the utilization of mathematical optimization within SAP’s software.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200513005232/en/
“Mathematical optimization continues to be an important cornerstone along with our accelerated investment into intelligent algorithms such as AI/ML,” said SAP Senior Vice President of Development for Digital Supply Chain Franz Hero. “Combining these approaches will offer our customers a differentiated set of advanced tools for better automation and decision support.”
The Gurobi Optimizer has been a key component of SAP’s supply chain management solutions since 2015.
Under the 10-year Enterprise Agreement signed by SAP and Gurobi:
- The Gurobi Optimizer is utilized by the SAP® Integrated Business Planning for Supply Chain (SAP IBP) solution. SAP will look for new opportunities to embed the Gurobi Optimizer into other applications that benefit from mathematical optimization.
- Gurobi’s R&D department will commence a strategic cooperation with SAP, and will provide focused innovation support and consulting to SAP in all matters related to mathematical optimization.
“SAP and Gurobi share the same vision: to empower companies to benefit from mathematical optimization by using it to make optimal, data-driven decisions in this era of the Intelligent Enterprise. SAP and Gurobi will be working more closely together to spearhead greater innovation and adoption of mathematical optimization across SAP’s enterprise applications,” said Dr. Edward Rothberg, CEO of Gurobi Optimization.
About SAP
As the Experience Company powered by the Intelligent Enterprise, SAP is the market leader in enterprise application software, helping companies of all sizes and in all industries run at their best: 77% of the world’s transaction revenue touches an SAP system. Our machine learning, Internet of Things (IoT), and advanced analytics technologies help turn customers’ businesses into intelligent enterprises. SAP helps give people and organizations deep business insight and fosters collaboration that helps them stay ahead of their competition. We simplify technology for companies so they can consume our software the way they want – without disruption. Our end-to-end suite of applications and services enables more than 440,000 business and public customers to operate profitably, adapt continuously, and make a difference. With a global network of customers, partners, employees, and thought leaders, SAP helps the world run better and improve people’s lives. For more information, visit www.sap.com.
About Gurobi Optimization
Gurobi produces the world’s fastest and most powerful mathematical optimization solver – the Gurobi Optimizer – which is used by leading global companies across more than 40 different industries to rapidly solve their complex, real-world problems and make automated decisions that optimize their efficiency and profitability.
As the market leader in mathematical optimization software, we aim to deliver not only the best solver, but also the best support – so that companies can fully leverage the power of mathematical optimization (on its own or in combination with other AI techniques such as machine learning) to drive optimal business decisions and outcomes.
Founded in 2008, Gurobi has operations across the USA, Europe, and Asia and more than 2,400 customers globally including SAP, Air France, Uber, and the National Football League (NFL). For more information, please visit https://www.gurobi.com/ or call +1 713 871 9341.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200513005232/en/
Contact information
Isela Warner
Gurobi Optimization, LLC
775-771-2826
warner@gurobi.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Okomera Strengthens Its Leadership Team With the Appointment of Marion Ghibaudo as Chief Technology Officer16.9.2026 09:00:00 EEST | Press release
Okomera, a TechBio company pioneering next-generation cancer care through the development of a proprietary technology platform combining tumor mini-avatars, microfluidics, and AI-powered imaging, today announced the appointment of Marion Ghibaudo as Chief Technology Officer. She will spearhead the company’s technology and innovation strategy and lead the industrial deployment of its integrated hardware, software, and biological platform. Marion Ghibaudo will join Okomera’s Executive Committee and report to CEO Silvère Lucquin. In parallel, Raphaël Tomasi, Okomera’s co-founder and former CTO, transitions to the role of VP Platform, ensuring continuity in the development of the company’s technology platform. Marion’s appointment comes at a key stage in Okomera’s growth as the company advances toward pilot studies, industrial scale-up, and commercialization. Okomera has developed a proprietary technology platform that transforms patient biopsies into multiple miniaturized tumor avatars, e
Galderma’s Restylane ® Volyme™ Demonstrates High Effectiveness, Satisfaction and a Robust Safety Profile in Chinese Patients With Temple Hollowing16.9.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD) today announced positive topline results from a study of Restylane Volyme for the correction of moderate-to-severe temple hollowing in 162 patients in China.1 The study met its primary endpoint, demonstrating the effectiveness and safety of Restylane Volyme versus a no-treatment control, while also achieving high patient and investigator satisfaction.1 These data further reinforce Galderma's ambition to expand its Restylane hyaluronic acid (HA) injectables portfolio in China, one of the world's fastest-growing aesthetics markets, through evidence generation that supports broader patient access and additional treatment areas.1-3 Powered by diverse NASHA®, NASHA HD™, and OBT™ technologies, Restylane offers gels with the highest firmness to the highest flexibility, enabling personalized treatments that deliver structural support, natural-looking results, and a healthy glow.1,4-8 Restylane Volyme is a moderately soft and flexible gel made with OBT that distributes with
Nippon Electric Glass’s IR Transmitting Glass “FI-02” Adopted for Heimann Sensor Lens Unit, Enabling a 120° × 68° Field of View16.9.2026 04:00:00 EEST | Press release
Nippon Electric Glass Co., Ltd. (NEG) (TOKYO: 5214), a global leader in specialty glass headquartered in Otsu, Japan, announced that its IR Transmitting Glass (chalcogenide glass) “FI-02” has been adopted for Heimann Sensor GmbH’s wide-angle lens unit for thermal cameras. The lens unit achieves a 120° × 68° field of view, surpassing the previous product’s maximum of 92° × 59°. The adoption marks a significant milestone for FI-02 and showcases how advanced specialty glass can meet the demanding optical and manufacturing requirements of the expanding infrared sensing market. Thermal cameras detect infrared radiation emitted by people or objects and convert it into thermal images. Infrared sensors can detect the locations of people and temperature distributions. They are expected to be used for people detection and monitoring, where privacy considerations are important, and for air-conditioning control, while their use is expanding in healthcare, equipment monitoring, and security. Advanc
Workiva Advances Regulatory Work with AI Innovation15.9.2026 18:00:00 EEST | Press release
Workiva Inc. (NYSE: WK), a leading, audit-ready platform for trust, transparency, and accountability, unveiled dozens of new product and platform innovations at Amplify 2026, the company’s annual conference attended by thousands of finance, accounting, sustainability, risk, and compliance leaders. Workiva Debuts Agent Studio Workiva introduced Agent Studio, a landmark platform capability that empowers users to quickly build, customize, and deploy AI agents in Workiva's trusted platform. By combining AI reasoning with Workiva's native platform capabilities, enterprise knowledge, and governed workflows, Agent Studio enables users to automate sophisticated manual business processes without writing any code. Organizations can enrich agents with company-specific knowledge and context, tailor them to their own processes, and schedule automations to execute recurring work. “With Agent Studio, we're putting the power to build in the hands of the people who know the work and their company the b
Study: Heatwaves Increase Cough Urge, Which Salt Aerosols Reduce15.9.2026 16:15:00 EEST | Press release
SC Therapeutics, with University North Carolina, Imperial College London, and Boston University, announced publication on Tuesday in Nature Scientific Reports of results from a multi-institutional study indicating that the aridity inherent in heatwaves increases cough hypersensitivity in human airways by collapsing mucus onto cilia in a manner common to chronic respiratory diseases, such as cystic fibrosis, and asthma. The researchers find that alkaline aerosols of magnesium salts reverse mucosal collapse for several hours, and reduce cough hypersensitivity as reflected in placebo-adjusted suppression of daily cough bout rate (59%, p=0.03) and persistence of suppression post treatment for 1 to 3 weeks in a randomized, double-blind, placebo-controlled study of 10 refractory chronic cough patients. “Paris recorded 5,764 excess deaths between 17 June and 2 July, a period of time during which we report atmospheric aridity in the city increased approximately 3-fold relative to the 35 year a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom